{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:20:01Z","timestamp":1788542401972,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/background:<\/jats:title>\n                    <jats:p>\n                      Tuberculosis remains an important cause of mortality worldwide. Previous tuberculosis treatment is a strong determinant of multi-drug resistant tuberculosis. The study objective was to describe the mutations detected of\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) complex clinical strains screened with GeneXpert isolated from previously treated patients in C\u00f4te d'Ivoire.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Sputum collected and decontaminated by the n-acetyl-l-cysteine method was used to perform Ziehl\u2013Neelsen staining, GeneXpert MTB\/rifampicin, and culture on Lowenstein\u2013Jensen medium. Drug susceptibility testing (DST) for first-line drugs was performed in a Bactec 960 Automated System. After strain identification by antigen MPT64 detection, DNA extraction, and genotyping with MTBDRplus assay was performed and interpreted. The strains muted in rpoB without a specific protein identified and were sequenced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mutant sequences were detected in 60 sputum samples with GeneXpert MTB\/rifampicin of which 55 were confirmed multi-drug resistant MTB strains after DST. The most frequent mutations responsible for rifampin resistance were detected with MTBDRplus assay for 49 (81.7%) clinical strains, while sequencing was required for 11 (18.3%). H526Q mutation, L533P, and D516V associated respectively with L533P, A532A, and S522L, and were observed for three relapse cases. For these cases, GeneXpert and sequencing results were concordant. Discrepancies between GeneXpert and mycobacteria growth indicator tube-DST for rifampin were observed for three strains, on which D516Y, H526C, and L533P were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In the setting of a high prevalence of drug resistance, characterization of the genetic basis of MTB strains resistant to rifampin could be screened first with MTBDRplus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijmyco.2016.01.001","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:32:09Z","timestamp":1455669129000},"page":"142-147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Genotyping of mutations detected with GeneXpert"],"prefix":"10.4103","volume":"5","author":[{"given":"K N'guessan","family":"Kouassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alagna","family":"Riccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Dutoziet","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guei","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coulibaly","family":"F\u00e9rilaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seck-Angu","family":"Hortense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assand\u00e9","family":"Jean-marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cirillo Daniela","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dosso","family":"Mireille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20260904","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMp068273","article-title":"IM, XDR tuberculosis: implications for global public health","volume":"356","author":"Raviglione","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"R3-5-20260904","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0012-3692(15)50981-1","article-title":"Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control","volume":"130","author":"Sharma","year":"2006","journal-title":"Chest"},{"key":"R4-5-20260904","first-page":"231","article-title":"Primary resistance to antituberculosis drugs: trends in C\u00f4te d'Ivoire from 1996 to 2006","volume":"38","author":"Nguessan","year":"2008","journal-title":"Med. Mal. Infect"},{"key":"R5-5-20260904","first-page":"65","article-title":"Molecular detection of resistance to rifampin and Isoniazid among patients eligible for retreatment regimen in C\u00f4 te d'Ivoire in 2012","volume":"3","author":"N'Guessan","year":"2013","journal-title":"Adv. Infect. Dis"},{"key":"R6-5-20260904","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5588\/ijtld.11.0445","article-title":"Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis","volume":"16","author":"Smith","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R7-5-20260904","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1586\/erm.12.71","article-title":"Nucleic acid testing for tuberculosis at the point-of care in high-burden countries","volume":"12","author":"Niemz","year":"2012","journal-title":"Expert Rev. Mol. Diagn"},{"key":"R8-5-20260904","doi-asserted-by":"crossref","first-page":"e765333","DOI":"10.1371\/journal.pone.0076533","article-title":"Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis","volume":"8","author":"Arentz","year":"2013","journal-title":"PLoS ONE"},{"key":"R11-5-20260904","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1128\/JCM.02214-10","article-title":"Evaluation of the Cepheid Xpert MTB\/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens","volume":"49","author":"Marlowe","year":"2011","journal-title":"J. Clin. Microbiol"},{"key":"R12-5-20260904","doi-asserted-by":"crossref","first-page":"e1001061","DOI":"10.1371\/journal.pmed.1001061","article-title":"Comparison of Xpert MTB\/RIF with other nucleic acid Technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study","volume":"8","author":"Scott","year":"2011","journal-title":"PLoS Med"},{"key":"R13-5-20260904","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1573398X113099990015","article-title":"Using Xpert MTB\/RIF","volume":"9","author":"Mark","year":"2013","journal-title":"Curr. Respir. Med. Rev"},{"key":"R14-5-20260904","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/JCM.01209-09","article-title":"Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results","volume":"47","author":"Van Deun","year":"2009","journal-title":"J. Clin. Microbiol"},{"key":"R15-5-20260904","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1128\/JCM.01054-06","article-title":"Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculsosis with low and high level resistance","volume":"44","author":"Brossier","year":"2006","journal-title":"J. Clin. Microbiol"},{"key":"R16-5-20260904","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1128\/JCM.00083-06","article-title":"Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy","volume":"44","author":"Miotto","year":"2006","journal-title":"J. Clin. Microbiol"},{"key":"R17-5-20260904","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JCM.02741-12","article-title":"Mutations tuberculosis isolates with specific rpoB liquid culture system for Mycobacterium rifampin resistance missed in automated","volume":"51","author":"Rigouts","year":"2013","journal-title":"J. Clin. Microbiol"},{"key":"R18-5-20260904","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1128\/AAC.49.6.2200-2209.2005","article-title":"Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis","volume":"49","author":"McCammon","year":"2005","journal-title":"Antimicrob. Agents Chemother"},{"key":"R19-5-20260904","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/1469-0691.12517","article-title":"Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array","volume":"20","author":"Huang","year":"2014","journal-title":"Clin. Microbiol. Infect"},{"key":"R20-5-20260904","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2180-9-39","article-title":"Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America","volume":"9","author":"Dalla Costa","year":"2009","journal-title":"BMC Microbiol"},{"key":"R21-5-20260904","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1128\/AAC.46.5.1417-1424.2002","article-title":"High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from north western Russia 1996 to 2001","volume":"46","author":"Mokrousov","year":"2002","journal-title":"Antimicrob. Agents Chemother"},{"key":"R22-5-20260904","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1128\/JCM.02489-13","article-title":"Mixed Mycobacterium tuberculosis complex infections and falsenegative results for rifampin resistance by GeneXpert MTB\/ RIF are associated with poor clinical outcomes","volume":"52","author":"Zetola","year":"2014","journal-title":"J. Clin. Microbiol"},{"key":"R23-5-20260904","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1128\/JCM.01683-10","article-title":"Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga district, Malawi","volume":"48","author":"Mallard","year":"2010","journal-title":"J. Clin. Microbiol"},{"key":"R24-5-20260904","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1016\/j.ijid.2013.06.006","article-title":"Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case-control study","volume":"17","author":"Songhua Chen","year":"2013","journal-title":"Int. J. Infect. Dis"},{"key":"R25-5-20260904","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/thx.2005.045963","article-title":"Risk factors for multidrug resistant tuberculosis in Europe: a systematic review","volume":"61","author":"Faustini","year":"2006","journal-title":"Thorax"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553116000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553116000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01929415-201605020-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:01:49Z","timestamp":1788541309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01929415-201605020-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijmyco.2016.01.001","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}